Antithrombotics in Complex Percutaneous Coronary Interventions: Type and Duration of Treatment-Reference-Cited by-同舟云学术

Antithrombotics in Complex Percutaneous Coronary Interventions: Type and Duration of Treatment

Published:2021-10-13 Issue: Volume:15 Page:
ISSN:1758-390X
Container-title:US Cardiology Review
language:en
Short-container-title:

Author:

Benetou Despoina-Rafailia¹^ORCID,Varlamos Charalampos¹^ORCID,Pappas Christos¹,Kolokathis Fotios¹,Alexopoulos Dimitrios¹^ORCID

Affiliation:

1. Second Department of Cardiology, Attikon University Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece

Abstract

Patients undergoing complex percutaneous coronary intervention (PCI) are at an increased risk of atherothrombotic complications. Although dual antiplatelet therapy is the mainstay of treatment for patients undergoing PCI with stent implantation, deciding its type and duration in complex PCI patients has long been considered a challenge for clinicians. This is because the beneficial effects of prolonged treatment and/or more potent antiplatelet agents’ use in preventing ischemic events are hindered by a concomitant increase in bleeding complications. The aim of this review is to highlight current evidence regarding the optimal antithrombotic therapy regimens used in complex PCI patients, focusing on the evaluation of both safety and efficacy outcomes as well as addressing future perspectives.

Publisher

Radcliffe Group Ltd

Subject

Cardiology and Cardiovascular Medicine

Reference27 articles.

1. Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J 2018;39:213–60. https://doi.org/10.1093/eurheartj/ehx419; PMID: 28886622

2. Bortnick AE, Epps KC, Selzer F, et al. Five-year follow-up of patients treated for coronary artery disease in the face of an increasing burden of co-morbidity and disease complexity (from the NHLBI Dynamic Registry). Am J Cardiol 2014;113:573–9. https://doi.org/10.1016/j.amjcard.2013.10.039; PMID: 24388624.

3. Werner N, Nickenig G, Sinning JM. Complex PCI procedures: challenges for the interventional cardiologist. Clin Res Cardiol 2018;107(Suppl 2):64–73. https://doi.org/10.1007/s00392-018-1316-1; 29978353; PMID: 29978353.

4. Stefanini GG, Serruys PW, Silber S, et al. The impact of patient and lesion complexity on clinical and angiographic outcomes after revascularization with zotarolimus- and everolimus eluting stents: a substudy of the RESOLUTE All Comers Trial (a randomized comparison of a zotarolimus-eluting stent with an everolimus-eluting stent for percutaneous coronary intervention). J Am Coll Cardiol 2011;57:2221–32. https://doi.org/10.1016/j.jacc.2011.01.036; PMID: 21616282.

5. Wilensky RL, Selzer F, Johnston J, et al. Relation of percutaneous coronary intervention of complex lesions to clinical outcomes (from the NHLBI Dynamic Registry). Am J Cardiol 2002;90:216–21. https://doi.org/10.1016/S0002-9149(02)02457-8; PMID: 12127606.